NIPER Hajipur, Boehringer Ingelheim Sign MoU to Boost Pharma Research and Next-Generation Therapies
A key feature of the MoU is Boehringer Ingelheim’s decision to provide researchers access to its opnMe open science platform. This platform is expected to enable wider scientific exchange, support collaborative drug discovery, and help researchers work on healthcare innovation with industry-grade research tools and scientific resources.